GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kymera Therapeutics
Kymera Therapeutics is a biotech pioneer in targeted protein degradation. Its stock price represents a venture bet on a revolutionary new treatment technology. The chart reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Oncology targeted therapy
Kymera is a biotech company pioneering targeted protein degradation for the treatment of cancer and immune diseases. We classify it as a member of the targeted oncotherapy sector, and the chart below reflects the general trends and sentiment in this cutting-edge field of biotechnology.
Broad Market Index - GURU.Markets
Kymera Therapeutics is a biotech company pioneering targeted protein degradation, developing drugs that direct cells to destroy disease-causing proteins. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
KYMR - Daily change in the company's share price Kymera Therapeutics
For Kymera Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about its platform's clinical trials. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative oncology.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Kymera Therapeutics, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with KYMR's performance, which hinges on the results of clinical trials of its protein degradation platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Kymera Therapeutics is a biopharmaceutical company, a pioneer in the field of targeted protein cleavage. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Kymera's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kymera Therapeutics
Kymera is a biotech company developing targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Kymera Therapeutics, Inc. is a biotech company pioneering the development of a new class of drugs that exploit protein degradation mechanisms. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge biotech.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kymera Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kymera Therapeutics
Kymera Therapeutics, a biotech company at the forefront of targeted protein degradation, shows sharp monthly fluctuations not in current sales but in news about progress in clinical trials of its innovative drugs, which could change the treatment of cancer and autoimmune diseases.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company specializing in a novel "targeted protein degradation" technology for drug development, primarily for cancer and immune diseases. The chart below shows the overall dynamics of the biotech sector, where investors are evaluating the potential of breakthrough scientific platforms.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kymera Therapeutics is a pioneer in developing a new class of drugs that utilize the body's natural defenses to "destroy" disease-causing proteins. The chart below shows general market trends, but Kymera shares move with clinical trial news, not the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kymera Therapeutics
Kymera Therapeutics, a biotech company developing innovative drugs that target disease-causing proteins, has seen its weekly stock price move in direct response to preclinical and clinical trial data, a trend typical of companies at the cutting edge of science and associated with high volatility.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Biotech companies working in targeted therapy, like Kymera, are riding the wave of industry-wide news about scientific breakthroughs. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives Kymera's unique platform compared to other companies in the field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kymera Therapeutics is a biotech company developing a new class of drugs that exploit protein degradation mechanisms. This is cutting-edge science. The chart shows that its shares exist in a world of their own, where any news from the lab is more important than any macroeconomic data.
Market capitalization of the company, segment and market as a whole
KYMR - Market capitalization of the company Kymera Therapeutics
Kymera Therapeutics' market capitalization reflects investor valuation of its cutting-edge protein degradation platform. The chart reflects market confidence that its technology, which allows it to "destroy" diseased proteins, will open up new avenues for treating cancer and immune diseases. Its high valuation demonstrates the enormous potential of this new approach in pharmaceuticals.
KYMR - Share of the company's market capitalization Kymera Therapeutics within the market segment - Oncology targeted therapy
Kymera Therapeutics is a pioneer in the emerging field of targeted protein degradation. Its market share reflects the potential of its platform to develop drugs that not only block but completely destroy disease-causing proteins, particularly in oncology.
Market capitalization of the market segment - Oncology targeted therapy
This graph shows the total market value of the entire biotech sector focused on targeted cancer therapy. For Kymera Therapeutics, which is developing a revolutionary protein-degrading technology, this line demonstrates the scale of the market. The rising graph reflects hopes for a new class of drugs that destroy, rather than block, disease-causing proteins.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kymera Therapeutics is a pioneer in targeted protein cleavage, a new approach to treating diseases. Its market capitalization reflects its revolutionary scientific platform. This represents the market share that investors are willing to allocate to fundamentally new approaches to drug discovery.
Book value capitalization of the company, segment and market as a whole
KYMR - Book value capitalization of the company Kymera Therapeutics
Kymera Therapeutics is a pioneer in targeted protein degradation. Its book value is derived from its scientific platform and the financial reserves it has to support clinical trials. This is the foundation for developing a new class of drugs. How has this capital changed as its revolutionary technology has developed? The chart below shows this story.
KYMR - Share of the company's book capitalization Kymera Therapeutics within the market segment - Oncology targeted therapy
Kymera Therapeutics is a pioneer in targeted protein cleavage. Its scientific breakthroughs are supported by a robust infrastructure: its own research platform, laboratories, and equipment for developing new classes of drugs. The chart shows the company's share of the R&D infrastructure in this cutting-edge biotech field.
Market segment balance sheet capitalization - Oncology targeted therapy
Kymera Therapeutics is a pioneer in developing a new class of drugs. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Kymera is an R&D company, its capital not in factories, but in a patented platform for creating protein-degrading drugs.
Book value of all companies included in the broad market index - GURU.Markets
Kymera Therapeutics is a pioneer in protein degradation, a new era in medicine. Its book value is derived from its cutting-edge Pegasus platform, laboratories, and clinical research capital. The chart shows the material foundation upon which drugs are created that can fundamentally "turn off" diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kymera Therapeutics
Kymera Therapeutics' balance sheet is made up of labs and capital. But the market sees a revolutionary drug discovery platform. The chart shows a huge "hope factor": a premium on the potential of its technology to "destroy" disease-causing proteins, which could transform medicine.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech pioneering the field of targeted protein degradation—a new approach to fighting disease. Its valuation is based on the potential of this revolutionary platform. The chart demonstrates investor optimism about the future of this approach.
Market to book capitalization ratio for the market as a whole
Kymera Therapeutics is a biotech pioneer in targeted protein degradation. Its technology eliminates, rather than blocks, disease-causing proteins. This chart shows the overall valuation, but how does the market value this company pioneering a potentially revolutionary approach to medicine?
Debts of the company, segment and market as a whole
KYMR - Company debts Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biotechnology company, and its financial strategy is entirely focused on bringing its drugs to market. Available capital, including potential debt, is used to advance several promising candidates through the costly and risky clinical trials process.
Market segment debts - Oncology targeted therapy
Kymera Therapeutics is a pioneer in targeted protein cleavage, a promising approach to treating cancer and immune diseases. Translating this science into a drug is a long and expensive process. This chart shows how the company raises capital to fund its innovative clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kymera Therapeutics
Kymera Therapeutics is a biotech pioneering targeted protein degradation—a novel approach to treating diseases. This chart shows its financial position. While in clinical trials, the company funds its expensive development primarily with equity, avoiding significant debt.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Developing innovative protein-degrading drugs like Kymera is at the cutting edge of biotechnology, requiring massive investment. This chart illustrates how the sector as a whole finances its risky projects. It allows one to assess Kymera Therapeutics' financial model and its reliance on external capital against the broader pharmaceutical industry.
Debt to book value of all companies in the market
This chart shows the overall "credit appetite" of the entire economy. Kymera Therapeutics, a biotech company in the R&D stage, relies on venture capital for its funding. The comparison with the broader market, dominated by profitable corporations, clearly demonstrates how different a financial model based on faith in science is from traditional economics.
P/E of the company, segment and market as a whole
P/E - Kymera Therapeutics
This chart for Kymera Therapeutics, a biotech developing drugs based on protein degradation, illustrates high expectations. Like many research-stage biotechs, its value is based on faith in the revolutionary potential of its platform, not on current profits. It's a bet on a new approach to treating disease.
P/E of the market segment - Oncology targeted therapy
Targeted therapy development, as Kymera is doing, is at the forefront of oncology. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Kymera is valued as a scientific platform whose "protein degradation" technology could open up a new way to treat cancer, and its valuation is based on this future potential.
P/E of the market as a whole
Kymera Therapeutics is a biotech pioneering targeted protein degradation—a novel approach to treating diseases that destroys, rather than blocks, disease-causing proteins. This chart reflects investors' overall risk appetite. It helps us understand whether KYMERA's high valuation is based on faith in its revolutionary platform or whether it's moving in sync with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kymera Therapeutics
Kymera Therapeutics is a biotech pioneering targeted protein cleavage—a novel approach to treating diseases including cancer and immune disorders. This chart reflects the high investor expectations for its innovative platform. Its momentum reflects a bet that this technology will lead to the creation of revolutionary drugs.
%20P%2FE%20Kymera%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kymera-Therapeutics&v=1772676053239 "Chart of the company's future (projected) P/E Kymera Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
Kymera Therapeutics is a pioneer in targeted protein cleavage, an innovative approach to treating diseases by addressing their root causes at the protein level. This chart displays the company's future profitability expectations, providing insight into how the market values the potential of this cutting-edge therapeutic platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772676053264 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Kymera Therapeutics is a biotech company developing a new class of drugs that harness the body's natural mechanism for breaking down disease-causing proteins. This is cutting-edge science. The company's valuation is not tied to general market forecasts, but depends entirely on the success of its innovative platform.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772676053290 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kymera Therapeutics
Kymera Therapeutics is a biotech pioneering targeted protein cleavage—a novel approach to treating cancer and immune diseases. Its current financial results reflect investments in research. This chart shows how much the company is investing in its revolutionary platform, which has the potential to transform drug development.
Profit of companies in the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company developing a new class of drugs that utilize targeted protein degradation. This approach has the potential to treat diseases previously considered untreatable. This graph reflects the high profit potential of the advanced biotech sector, where scientific breakthroughs create entire new markets.
Overall market profit
Kymera Therapeutics is a biotech company developing a new class of drugs (targeted protein degradation). Its success depends on scientific breakthroughs. However, funding lengthy and expensive research requires a favorable investment climate. This chart, reflecting market conditions, impacts Kymera's capital availability.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kymera Therapeutics
Kymera Therapeutics is a biotech company pioneering targeted protein degradation. Its technology enables the creation of drugs that destroy, rather than block, disease-causing proteins. This graph reflects analyst expectations, which essentially represent an estimate of the potential of this revolutionary platform and future clinical successes.
%20profit%20of%20the%20company%20Kymera%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kymera-Therapeutics&v=1772676053313 "Graph of future (projected) profit of the company Kymera Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company developing a new class of drugs based on targeted protein degradation (TPD). This technology allows for the "destruction" of disease-causing proteins, rather than simply blocking them. This chart shows profitability projections for the biotech sector, providing context for assessing the potential of Kymera's revolutionary platform for treating cancer and other diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772676053315 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Kymera Therapeutics is a biotechnology company developing a new class of drugs that exploit protein degradation mechanisms. Its value and prospects are entirely dependent on the success of its scientific platform and clinical trials. Macroeconomic trends reflected in this market earnings forecast are irrelevant to assessing its long-term potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772676053321 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kymera Therapeutics
Kymera Therapeutics is a biotech company developing a new class of drugs using targeted protein degradation. This chart shows the market valuation of its potential. Its high valuation relative to zero sales reflects investors' faith in its revolutionary scientific platform.
P/S market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company developing a new class of drugs that utilize targeted protein degradation mechanisms to treat oncology and immune diseases. This chart shows the average revenue estimate in the biotech sector. It helps understand how highly investors value the potential revenue from Kymera's innovative platform.
P/S of the market as a whole
Kymera Therapeutics is at the forefront of a new field in medicine: targeted protein degradation. Their technology enables them to not just block, but completely destroy proteins that cause diseases like cancer. This graph provides a general revenue benchmark against which to judge the enormous expectations investors have for KYMR's breakthrough science.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kymera Therapeutics
Kymera Therapeutics is a biotech company pioneering targeted protein cleavage. This innovative technology allows for the destruction of disease-causing proteins, rather than simply blocking them. This chart reflects the high expectations of investors for the future of this platform, which has the potential to create an entirely new class of drugs.
%20P%2FS%20Kymera%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kymera-Therapeutics&v=1772676053368 "The graph of the company's future (projected) P/S Kymera Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
Kymera Therapeutics is a pioneer in targeted protein degradation, a new approach to drug development that offers treatment for diseases previously considered incurable. This chart compares the market's lofty expectations for its innovative platform with those for the risky but promising biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772676053373 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Kymera Therapeutics is a biotech company developing a new class of drugs that harness the body's natural mechanism for breaking down disease-causing proteins. This chart, reflecting investor appetite for breakthrough technologies, is important for Kymera. Market optimism allows such innovative companies to more easily raise capital for their long-term, risky research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772676053376 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kymera Therapeutics
Kymera Therapeutics is a biotech pioneer in targeted protein degradation (TPD). This chart reflects revenue, which at this stage primarily comes from strategic alliances with large pharmaceutical companies for co-development of drugs. It demonstrates the financial support for this innovative scientific platform.
Sales of companies in the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotechnology company pioneering targeted protein cleavage—a novel approach to treating diseases. Its activities are segmented into various drug development programs. This chart depicts the financial flows associated with one of its lead candidates, highlighting its clinical and commercial potential.
Overall market sales
Kymera Therapeutics is a biotech company developing a new class of drugs that utilize targeted protein cleavage. This innovative approach could potentially treat diseases previously considered incurable. Kymera's success depends on scientific breakthroughs, and the company exemplifies how fundamental science is creating a new economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kymera Therapeutics
Kymera Therapeutics is a biotechnology company pioneering targeted protein cleavage (TPD), a novel approach to treating diseases. Its future sales forecast reflects the market's assessment of the potential of its innovative platform for developing drugs that can target proteins that cause diseases previously considered drug-resistant.
%20sales%20of%20the%20company%20Kymera%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kymera-Therapeutics&v=1772676053407 "Schedule of future (projected) sales of the company Kymera Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company developing a new class of drugs that harness the body's natural mechanisms to destroy disease-causing proteins. This chart shows expectations for the entire targeted therapy sector, reflecting analysts' views on the potential of innovative approaches to treating cancer and immune diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772676053410 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Kymera Therapeutics, a biotech company developing a new class of drugs (targeted protein degradation), is at the forefront of science. Its funding and valuation depend on investors' risk appetite. This chart of total sales forecasts reflects the state of the economy, which affects the availability of capital for innovation.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772676053417 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kymera Therapeutics
Kymera Therapeutics is a biotechnology company pioneering targeted protein degradation—a novel approach to treating diseases, including cancer. This chart reflects its financial performance at the clinical trial stage, where significant investments in research are the foundation for future therapeutic breakthroughs and profitability.
Market segment marginality - Oncology targeted therapy
Kymera Therapeutics is a biotech pioneer in targeted protein cleavage (TPD). This technology allows for the "destruction" of disease-causing proteins, rather than simply blocking them. This graph provides insight into the potential operational effectiveness of this breakthrough scientific platform, which has the potential to transform the treatment of many diseases.
Market marginality as a whole
Kymera Therapeutics is a biotech company developing a new class of drugs that utilize the body's natural mechanism for breaking down disease-causing proteins. Its value is based on the potential of this innovative platform. This chart shows the profitability of mature businesses, while KYMR's success depends on scientific breakthroughs and clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Kymera Therapeutics
Kymera Therapeutics is a pioneer in targeted protein degradation, a new approach to treating diseases. This chart shows the growth of its scientific team. This increase in intellectual capital is a direct indicator of progress in developing this innovative therapeutic platform.
Share of the company's employees Kymera Therapeutics within the market segment - Oncology targeted therapy
Kymera Therapeutics is a pioneer in targeted protein degradation, a new approach to treating diseases. Its research requires a world-class team of scientists. This chart shows the scale of its talent in this cutting-edge field of biotechnology, reflecting its ambition to create a new class of drugs.
Number of employees in the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company specializing in a novel protein degradation technology for drug development. This chart reflects activity in the targeted oncology sector. The explosive growth of scientists in this cutting-edge field reflects the race to develop a new class of drugs capable of treating previously intractable diseases.
Number of employees in the market as a whole
Kymera Therapeutics is a biotech company developing a new class of drugs. Its success depends on scientific innovation, but a strong economic environment, symbolized by this chart, is critical to attracting investment in long-term, risky projects and to the future market acceptance of new therapies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kymera Therapeutics (KYMR)
Kymera Therapeutics is a biotech company developing a new class of drugs that exploit protein degradation mechanisms. Its valuation is based on the potential of its scientific platform. The astronomically high market capitalization per employee, visible in this chart, reflects investors' bet that its team of scientists will be able to create breakthrough drugs.
%20of%20the%20company%20Kymera%20Therapeutics%20(KYMR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kymera-Therapeutics-KYMR&v=1772676053615 "Chart of market capitalization per employee (in thousands of dollars) of the company Kymera Therapeutics (KYMR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Kymera (KYMR) is a clinical-stage biotech working on a "protein degrader" (PROTAC). Its value is derived from pure R&D. This chart shows the (speculative) market value the market attributes to each elite scientist, not its current operations.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772676053640 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Kymera Therapeutics is a biotech company developing a new class of drugs that harness the body's natural mechanism to destroy disease-causing proteins. This cutting-edge science has enormous potential. The chart reflects the market's high speculative valuation of the work of this innovative team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772676053646 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kymera Therapeutics (KYMR)
Kymera Therapeutics is a biotech company specializing in targeted protein degradation (TPD), a new way to fight diseases, including cancer. Being in the clinical stage, they are likely unprofitable. This chart shows how much capital is invested in each scientist working on this cutting-edge R&D platform, in hopes of creating breakthrough drugs.
%20Chart%20Kymera%20Therapeutics%20(KYMR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kymera-Therapeutics-KYMR&v=1772676053705 "Company Profit Per Employee (in thousands of dollars) Chart Kymera Therapeutics (KYMR)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Kymera (KYMR) is an R&D company, a pioneer in "targeted protein degradation" (cancer treatment, immunology). This chart shows the benchmark for "oncology targeted therapy." In this R&D sector, the benchmark is *negative*. Companies are burning billions on R&D. Profit per scientist is a distant goal.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772676053831 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Kymera Therapeutics (KYMR) is a biotech company pioneering the field of "targeted protein degradation." Their platform (Pegasus) creates molecules that induce cells to destroy disease-causing proteins. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772676053834 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kymera Therapeutics (KYMR)
Kymera Therapeutics is a biotech company developing a new class of drugs that exploit protein degradation mechanisms. While in the research stage, it may not generate revenue. This timeline will indicate whether its cutting-edge scientific platform can lead to the creation of commercially successful, high-yield drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kymera-Therapeutics-KYMR&v=1772676053853 "Sales chart per company employee Kymera Therapeutics (KYMR)")
Sales per employee in the market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company developing a new class of drugs using the protein targeting action (PROTAC) mechanism to combat cancer and immune diseases. This chart shows revenue per employee. The comparison to the segment reflects the effectiveness of their innovative R&D platform on the path to commercialization.
Sales per employee for the market as a whole
Kymera Therapeutics is a biotech company developing a new generation of drugs that utilize the "protein targeting actionable (PROTAC)" mechanism. They are in the clinical stage. Like other biotechs at this stage, they likely do not yet have commercial revenue. This graph will reflect $0 or partnership revenue, as the company's focus is on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Kymera Therapeutics (KYMR)
Kymera Therapeutics is a biotech company working in the cutting-edge field of "targeted protein degradation" (TPD). They're trying not to block "bad" proteins, but to force the body to destroy them. It's revolutionary, but scientifically very complex. This chart shows the number of skeptics who believe this technology is still very much in its infancy and far from successful.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kymera-Therapeutics-KYMR&v=1772676053891 "Short Shares Chart for the Company Kymera Therapeutics (KYMR)")
Shares shorted by market segment - Oncology targeted therapy
Kymera Therapeutics (KYMR) is a biotech company using advanced protein targeting and degradation (PROTAC) technology to create drugs that destroy disease-causing proteins (primarily cancer). This chart shows the odds against the biotech sector working on PROTACs, reflecting investor skepticism about this new and complex scientific platform.
Shares shorted by the overall market
Kymera (KYMR) is a clinical-stage biotech (targeted therapy). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives KYMR of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kymera Therapeutics (KYMR)
Kymera Therapeutics is a clinical-stage biotech company, a pioneer in protein degradation. Its stock is highly speculative. This chart for KYMR can soar above 70 on positive R&D data. A range below 30 often reflects research setbacks, safety concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kymera-Therapeutics-KYMR&v=1772676053948 "RSI 14 indicator chart for the company's stock Kymera Therapeutics (KYMR)")
RSI 14 Market Segment - Oncology targeted therapy
Kymera (KYMR) is a biotech company working on "protein degradation" (PROTAC). Their therapy doesn't "block" disease, but "destroys" its cause. RSI_14_Seg for "Oncology" (biotech) reflects the overall sentiment. It helps us understand: is KYMR's volatility a reflection of their breakthrough platform or general sector hype?
RSI 14 for the overall market
Kymera Therapeutics (KYMR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KYMR (Kymera Therapeutics)
Kymera Therapeutics is a biotech company developing a new generation of drugs that utilize targeted protein degradation (TPD). This approach allows for the "destruction" of diseased proteins. This chart shows the average analyst forecast. It represents their collective assessment of the scientific potential of Kymera's platform and the risks associated with R&D.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KYMR-Kymera-Therapeutics&v=1772676053982 "A chart showing analyst consensus forecasts for the expected stock price. KYMR (Kymera Therapeutics)")
The difference between the consensus estimate and the actual stock price KYMR (Kymera Therapeutics)
Kymera Therapeutics is a biotech company, a leader in the development of protein degradation products (PROTACs). This technology doesn't block bad proteins, but destroys them. This chart shows the difference between the consensus estimate and the price. It reflects analysts' belief in the breakthrough potential of this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KYMR-Kymera-Therapeutics&v=1772676053985 "A chart showing the difference between the consensus forecast and the actual stock price. KYMR (Kymera Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Kymera Therapeutics is a biotech company working at the cutting edge of science. It develops "protein degraders" (PROTACs)—a new way to destroy cancer-causing proteins. This chart shows general expectations for the oncology sector, reflecting whether experts believe in the success of this risky but breakthrough technology.
Analysts' consensus forecast for the overall market share price
Kymera Therapeutics is a biotech company working on a breakthrough protein-degrading technology (PROTAC). Rather than blocking the bad protein, it forces the cell to destroy it. This chart shows overall market sentiment. For Kymera, at the cutting edge of science, it's important to understand how the overall risk appetite (analyst sentiment) influences funding for their revolutionary platform. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kymera Therapeutics
Kymera Therapeutics (KYMR) is a biotech company, a leader in a hot new field: targeted protein degradation (TPD). Rather than blocking the disease-causing protein, they create drugs that target it for destruction. This chart represents a high-risk R&D bet. Its valuation is based on faith in this revolutionary scientific platform and their early clinical data.
AKIMA Market Segment Index - Oncology targeted therapy
Kymera is a biotech leader in a new technology: targeted protein degradation (TPD). Instead of blocking bad proteins (as everyone else does), their Pegasus platform uses the body's own system to completely destroy them. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Kymera's futuristic TPD platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Kymera is a biotech company, a pioneer in targeted protein degradation (TPD). This is a new treatment (cancer, immunology) that destroys diseased proteins. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story fits into the context of overall economic trends.
